Anand Patel: Our poster (3192) on allo-HCT in MPN-AP/BP in the current era of myeloid therapies at ASH23

Quoting Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of Chicago, on X/Twitter:

“Our poster (3192) on allogeneic hematopoietic cell transplantation (allo-HCT) in Accelerated Phase of Myeloproliferative Neoplasms/Blast Phase (MPN-AP/BP) in the current era of myeloid therapies at the American Society of Hematology (ASH23).

-65 of 202 patients received allo-HCT.

-Median overall survival 2.3 years from the time of allo-HCT.

-No difference in overall survival based on first-line treatment for MPN-AP/BP or response prior to allo.”

Source: Anand Patel/X